Octreotide (Sandostatin)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Octreotide (Sandostatin), covering 2014-06-02 to 2017-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma [Phase 2]